PROJECT REPORT

2018

A word from the CEO

2018 at a glance

Meet the companies

What’s in it for the companies?

What’s in it for AstraZeneca?

What’s in it for the life science industry?

Creating a 4D life science reality

Our story so far

Interview with Magnus and Pernilla

Frequently asked questions

“An Unexpected Incubation Model“

Financial overview

Scientific partners / Sponsors

azbioventurehub.com

BioVentureHub team / Acknowledgements

CONTENT

........................3

.....................4-5

.....................6-7

........................8

........................9

.................10-11

.................12-13

.................14-15

.................16-17

......................18

......................19

......................20

......................21

......................22

......................23

The BioVentureHub continues to grow. During 2018, we welcomed 3 new companies: Cellink, Cline Scientific and Scandinavian Development Services; and filled the hub’s current capacity.

At the end of the year, there were 26 life science companies and 1 academic group co-locating with us at the heart of AstraZeneca’s R&D Gothenburg site.

Each new company or academic group adds more ingredients and flavours to the innovation experiment we’re cooking up in the BioVentureHub.

By daring to share and stimulating a 4D life science reality–combining Drugs, Diagnostics, Devices, Digital health–we are forming a modern, life science environment based on scientific curiosity and collaboration opportunities, rather than strict business plan recipes.

As we enter 2019 and the final year of our initial five-year funding, we are proud of what we have achieved so far and we’re very excited about the prospects and opportunities for continued growth moving forward.

In December, The Medici Group recognised the BioVentureHub as being “one of the most novel incubators in the world.” We are truly grateful for all the recognition, support and encouragement we receive, and we’re very much looking forward to collaborating with you to maintain our leading position and to develop this exciting innovation experiment in 2019 and beyond.

Magnus BjörsneCEO

3

A WORD FROMTHE CEO

“…one of the most novel incubators in the world”

The Medici Group (Dec. 2018)

26companies

Cellink establishes R&D lab

in BioVentureHub

Opinion article published in Life Science Sweden

Hosted “Turning science

into business” seminar with

AZ commercial leaders

Participated in panel on

industry-academic collaboration during

Almedalen Week.

Featured in Dagens Industri list of hottest

tech hubs

Hosted deal making seminar with Pharma

Ventures

Hosted a seminar with Testa Center

– Sweden’s new test bed for biologicals

Nano tech company, Cline Scientific,

moves into BioVentureHub

I-Tech celebrates successful IPO and move to new offices

Featured at Park Annual life

science event

54

DECNOVOKTSEPAUGJULJUNMAYAPRFEB MARJAN

Stockholm-based, SDS, opens office in BioVentureHub

2018AT A GLANCE

Recognized as “one of the most novel incubators” in the world

by The Medici Group

MEET THE COMPANIES

76

“We continued to provide the 3D-bioprinting/printing

community with high quality and well-designed products that will contribute to the future of

medicine.”

Itedale Namro Redwan, Scientific Officer

Cellink

“We grew our sales by 62%, deepened relationships with key customers and delivered a suc-

cessful IPO.”

Philip Chabaane, CEOI-Tech

“We were thrilled to enter our first global development and licensing agreement for our 1st in category Rx regimen integrating medicines with

intelligent dosing and digital capabilities.”

Martin Olovsson, CEOOnDosis

“We were proud to contribute with high resolution

chemical surface analysis to understand how the dinosaur,

Stenopterygius, functioned 180 million years ago.”

Per MalmbergNanoSIMS

WHAT WAS THE HIGHLIGHT FOR YOUR COMPANY IN 2018?

* Swecure left the BioVentureHub during 2018

LIPIGONPHARMACEUTICALS

Embedded at the heart of AstraZeneca Gothenburg, BioVentureHub companies become part of a unique, open and collaborative scientific community-with the same access to the facilities as AstraZeneca staff.

WHAT’S IN IT FOR THE COMPANIES?

WHAT’S IN IT FOR ASTRAZENECA?

98

EXAMPLES OF SCIENTIFIC ADVICE AND WORK

• 2nd opinion on outcome of in vivo experiments

• Advice on suitable pharmacology screening assay

• Choice of indication based on known mode of action

• Advice on choice of non-clinical target validation

• Practical approaches for regulatory work for clinical studies in different geographies

• Requirements for and benefit of orphan designation for development drugs

• Advice on choice of non-clinical target validation

• Formulation feasibility work

• NMR feasibility work

• Proprietary in vitro assays

• Exploratory experimental NMR work

• Access to scientific leadership

• Open doors and open innovation

• Growth

• A great place to work

• A great place to live

• A unique service offering

• Potential collaboration with other BioVentureHub companies

Delivering on our value of ‘We are entrepreneurial’ and our strategic ambition to be a great place to work, the BioVentureHub is stimulating a more dynamic scientific research environment at the AstraZeneca Gothenburg site.

Combining different value chains, ideas and perspectives - and using resources and capacity in a new way - the BioVentureHub exposes AstraZeneca to more science and provides the company with a unique catalyst for innovation on the Gothenburg site.

AstraZeneca has entered into a number of scientific collaborations with several of the companies in the BioVentureHub. As the BioVentureHub continues to develop, we will increasingly be able to develop mutual learning and generate future collaboration opportunities.

The BioVentureHub and AstraZeneca initiated the Spin-

out project in collaboration with Vinnova and a group of

international investors to establish new life science companies

based on promising research or technology projects that might not otherwise beprogressed. OnDosis is the first company resulting from

the Spin-out project.

Companies in a number ofother industries have been inspired

by our novel innovation model.For example, ABB launched

SynerLeap after various studytrips to the BioVentureHub.

Our collaboration with the Gothenburg School of

Economics has led to several research articles examining the

BioVentureHub innovation model being published in international

peer-reviewed, international journals, for example:

INFRASTRUCTURE

• Access to database of scientific subcontractors and tools for requesting quotations

• Possibilities to buy used AstraZeneca equipment

• Management of chemical and biological waste

• Specialized lab services (e.g autoclaving)

• Open Innovation as a facilitator for

corporate exploration.•

Connecting life science entrepreneurs with resources

and expertise: the role of iungens brokerage in life science

innovation.•

The institutional work of life science innovation leadership: the case of

a bio venture hub.

WHAT’S IN IT FOR THELIFE SCIENCE INDUSTRY?

1110

FACILITATING SCIENTIFIC EXCHANGE

The BioVentureHub provides life science companies and research groups with a unique opportunity to co-locate and interact with AstraZeneca’s sci-entists and state-of-the-art facilities and infrastructure, and with each other.

DEVELOPING PROJECT ASSESSMENTAND COMMERCIAL FORECASTING CAPABILITIES

By tapping into AstraZeneca’s project assessment, entrepreneurs can in-crease their chances of developing the full commercial value of their innova-tions and make value-based investment decisions sooner.

AstraZeneca established the BioVentureHub in 2014with the aim to stimulate innovation and to strengthencompetitiveness in the life science ecosystem in Sweden and Scandinavia. Here are some of the ways we’remaking this happen…

STIMULATING A 4D LIFE SCIENCE ENVIRONMENT

The BioVentureHub is attracting and bringing together talent and expertise across Drugs, Devices, Diagnostics & Digital health. This ‘complementarity’ is helping to enhance the value of the individual value chains.

SPINNING OUT VALUE

AstraZeneca and the BioVentureHub are collaborating with the Swedish Government to establish a new innovation model that breathes life into proj-ects that established companies have decided not to commercialise. As with the launch of OnDosis, these innovations can provide the basis for new businesses, and subsequently, new jobs.

SAVING COSTS AND ENABLING BUSINESS SUCCESS

Companies and research groups in the BioVentureHub have the possibility to access the same infrastructure and services that AstraZeneca gets. Besides significant cost savings, everything is optimised to enable business success.

“AstraZeneca’s BioVentureHub is an exciting innovation model

for strengthening competitiveness and collaboration in the life science

industry. It’s smart Swedish industry in action, serving as inspiration to other companies andindustries when it comes to generatingopportunites in the new industrial era.”

Mikael DambergSwedish Minister for Enterprise and innovation

“I’m very proud to have been part of creating AstraZeneca’s

BioVentureHub. Besides play-ing an important role in creating a

strong Swedish life science ecosystem, it is also inspiring large companies in other industries to open up and embrace new models of collaborative innovation. Large companies working together with small companies leads to more successful companies and, in turn, a more prosperous and sustainable society.

Jan-Olof JackeDirector General at Confederation of Swedish Enterprise

“From an academic perspective, the BioVentureHub is a fascinating study of how open

innovation groundwork can be implemented in practice. We can learn a lot from how the team has conceptualised, mobilised and operationalised a novel model of open innovation and then facilitated that model in everyday business.”

Björn Remneland WikhamnAssociate Professor at Göteborgs Universitet

“The BioVentureHub is an excellent example of how

unlocking knowledge exchange can fuel the growth of life science

companies and the industry as a whole. We are very proud to have been part of the

BioVentureHub journey. It’s a courageous concept has become an inspirational reality.”

Jenni NordborgNational Coordinator Life Sciences and

Head of Health at Vinnova

“The BioVen-tureHub is play-

ing an important role in the life science ecosystem in West Sweden

and Sweden as whole. Besides help-ing to attract new companies and com-

petence, it is exploring an exciting new busi-ness model based on the sharing economy.

Long-term growth, impact and innovation in the life science industry will be dependent on collabo-ration – that’s what the BioVentureHub is all about.”

Iris ÖhrnLife Science Investment Advisor

at Business Region Göteborg

DIAGNOSTICS

DIGITAL HEALTH

DEVICES / MEDTECH

DRUGS

CREATING A 4DLIFE SCIENCE REALITY

1312

Vicore PharmaNina Carlén

“Vicore Pharma has developed a unique platform technology to treat a wide range of unmet medical needs. Our main project is focused on idiopathic pulmonary fibrosis (IPF), a chronic, progressive lung disease for which there is no real effective treatment currently available for patients suffering from the condition.”

MölnlyckeMarina Craig

“We want to further expand our cell biology and analytical chemistry capabilities and explore collaboration opportunities across life science. We see the BioVentureHub as a great opportunity to build even more scien-tific evidence and insights into our work. We hope to achieve good networking and new opportunities together with AstraZeneca and the other companies in the BioVenture-Hub. We love the energy and the forward thinking, as well as the mix of all the knowledge and experienced people. The atmosphere in the BioVentureHub is great!”

LIV DiagnosticsJohan Bjurqvist

“Liv Diagnostics is devel-oping a new diagnostic tool to measure the migration behavior of tumor cells, which provides a predic-tive indicator of metastasis. This infor-mation is critical because metastasis causes 90% of all deaths in cancer. Our product, Cell-

RACE, provides direct and quantified information on the risk of metastasis by analyzing the

migration behavior of living cells.”

MentormateBjörn Stansvik

“Being invited to the BioVentureHub, and the support from AstraZeneca was pivotal to our decision to expand from the United States to Sweden. Not only that, actual projects with AstraZeneca have provided a strong initial base for our expansion. The co-location arrangement has been invaluable during our stay and greatly contributed to the collaborative relationship with AstraZeneca and has given us more credibility locally. We are excited to have worked with AstraZeneca on several impactful projects including, but not limited to, respiratory disease and patient education. We highly recommend the BioVentureHub!”

If we’re honest, we don’t have a blueprint or grand plan for the way forward. But by making it easier for life science experts with diverse backgrounds and complementary skills to meet and interact, we’re seeing that we are creating a melting pot in which collaborative innovation can flourish.

Here are examples of BioVentureHub companies from across four value chains who are helping us to form a modern life science environment.

Antaros Medical joins.5 companies in BVH.

Companies move from annex to heart of site

10 companies in BVH

US-based Mentormate joins. First international

company in BVH.Awarded key to city of

Gothenburg.

Mölnlycke, a world-leading global medical solutions

company, establishes R&D innovation unit in BVH.

Starts as an innovation experiment. Mintage

Scientific is first company to join in Jan 2014.

Vinnova, Carl Bennet AB, Västra Götalandsregionen and Göteborgs Stad invest SEK 39 million in 5-year

BVH funding

First academic group, NanoSIMS, moves in with 37 MSEK investment from Knut & Alice Wallenberg

Foundation.

Labiotech.eu include BVH in list of top 15 biotech incubators in Europe

OnDosis, first Spin-out company, moves in.

26 companies and 1 academic group in BVH

State visit by President of Chile, with King and Queen

of Sweden.

It started as an experiment to support AstraZeneca’s ambition to be more open towards the outside world. The first company, Mintage Scientific, moved in Jan 2014. External funding, leading to the current BioVentureHub model, was secured in Feb 2015. The experiment has developed and widened, and is going from strength to strength.

OUR STORY

1514

DEC2016

MAY2016

SEPT2015

JUN2015

SEPT2014

FEB2015

JAN2014

“Sustainability is a core part of our company culture. The BioVentureHub demonstrates our commitment to a sustainable life science ecosystem. Moreover, the diversity of the companies co-locating with us fosters an inclusive and innovative working environment and adds to the positive impact we can have together on healthcare.”

Katarina AgeborgPresident AstraZeneca AB, Executive Vice-President, Sustainability and Chief Compliance Office

“Having more companies on site, doing more science, can only be a good thing. By attracting world-class scientists and investors, the BioVen-tureHub is contributing to a more vibrant and attractive research environment, and is helping us achieve our vision of making AstraZenecaGothenburg one of the best R&D sites in the world.“

Elisabeth BjörkVice President Head CVMD GMed& Gothenburg Site Lead

“The BioVentureHub has increased our interface with the outside world. Being open to collaborate and willing to share are increasingly important fac-tors for successful drug development. The hub is also helping to galvanise the life science potential in this region so we can compete for talent on a global basis.”

Matti AhlqvistSite Director, AstraZeneca Gothenburg

WHAT´SNEXT?

NOV2017

JUN2017

MAY2017

JAN2017

DEC2018

MAY2018

DEC2017

Magnus Björsne awarded “Enabler of the Year” by Life Science Sweden.

3 drug companies, 2 digital health companies, 2 med-ical device companies and 1 diagnostic company join

during 2017.

Recognized as “one of the most novel

incubators” in the world by The Medici Group

What is the key to the success of the BVH?What impresses people is the courage AstraZeneca is showing to open up and let people in. We’re doing something that goes against the instincts of big pharma. That seems to fascinate people. This is all about using existing resources in a better way than we have used them before. We have created a model that is quite unique. It’s not only words, it actually works!

What is the real value for AstraZeneca?The BVH is helping to change the culture of the company. AZ employees get exposed to different attitudes, mindsets and ways of working. They are often thrilled to learn about new projects and new scientific approaches, and are very proud when they are asked to give their opinions and advice. AZ is doing this because we believe that we will all benefit from a stronger life science community.

How is the AZ BVH different to other incubators?A key difference is that we don’t focus on startups. We focus on helping companies that are approaching the “Valley of Death,” i.e. about to enter the development phase. The BVH companies have their intellectual property (IP) in place so we can

interact with them without risk of jeopardizing future IP. Compared to other incubators,

we don’t provide services such as business coaching, funding, business development support. What we do offer is access to world-class scientific, technical and strategic expertise, which very few others can offer.

What are the future plans?We want to continue to grow the

BioVentureHub and attract companies and more academic groups who get value from and add value to the BVH environment. We’re looking to facilitate BVH companies’ access to foreign markets through collaborations with AstraZeneca marketing companies across the world, e.g. China. We’re also looking at how we can offer BVH companies more flexible access to more AstraZeneca labs and centres of scientific excellence.

How are you enjoying your new role?It’s great. I’ve joined a strong, small, solution-oriented team with a can-do attitude. I get to meet and interact with lots of smart people and help them to help each other by facilitating knowledge exchange and business opportunities.

What are some of your main projects?One of my main projects is to develop a robust operating model for the BioVentureHub that will enable us to continue to grow in a structured and scalable way. I’m the main contact for the companies when they need specific scientific support that AstraZeneca can help them with. I’m also part of the AZ Mentoring team which aims to provide more companies in Sweden with access to AstraZeneca’s expertise and capabilities.

What have you learned in your first few months?I’ve worked at AstraZeneca for 25 years, and in my new role I’m seeing and learning about so many new dimensions about how the broader life science ecosystem works. I have a much better appreciation for how hard-working the small companies are and

how much focus they need to put on financing on top of delivering their strategic plan. I’m

also getting a better picture of the depth and breadth of expertise we have at AstraZeneca and that makes me feel very proud.

What do you hope to achieve moving forward?

Something that is very inspiring is that we are developing the life science ecosystem with the

BioVentureHub. Advances in science and technology are dramatically changing the life science landscape. We need to continue to facilitate interaction between people, companies and organisations that don’t normally interact and encourage them to work together and dare to share.

INTERVIEW WITHMAGNUS

INTERVIEW WITH PERNILLA

1716

Magnus Björsne, CEO Pernilla Isberg, COO

From a Facilities Management perspective theBioVentureHub challenges our existing processes,

which leads to innovation and new ways of working, adding value to the BioVentureHub companies

and AstraZeneca.

It’s very positive that more and more colleagues at AstraZeneca are interested in and engaging with the BioVenturehub. And, every day, our colleagues in the

hub companies inspire us and give us new perspectives on innovation and collaboration

The BioVentureHub is an important part of the life science cluster we are creating here in the Gothenburg region. It provides a blueprint for collaboration across

borders and promotes efficiency, creativity andsustainability in the life science ecosystem.

It’s fantastic to experience the buzz being generated by the BioVentureHub. It would be super cool if more

international companies join us in 2019.

Erica WoodrowFinance/Coordinator

Ramon NoguerasReal Estate

Annica JohanssonFacilities Management

Jamie SmithCommunications

FREQUENTLY ASKED QUESTIONS

AN UNEXPECTED INCUBATION MODEL

18

How many companies are there in the BioVentureHub (BVH)? As of 31 December 2018, there were 26 companies and 1 academic group in the BVH.

How many people are employed by the BVH companies? There are currently 135 people employed by the BVH companies.

What’s the maximum capacity for companies/people in the BVH? There’s no fixed limit. That said, we always assess whether there are synergies, both regarding AstraZeneca (AZ) interests and/or with respect to other companies in the BVH. We also make sure that we have capacity to take them on, in all respects.

How is the BVH funded? Non-facility related costs incurred by AstraZeneca are reimbursed by external funds – from four external investors: Vinnova, Carl Bennet AB, Region Västra Götaland and City of Gothenburg. The companies also pay a monthly rental fee.

How does confidentiality work with the external BVH companies? One of the drivers behind the BVH is knowledge sharing. To benefit from what you learn, knowledge sharing can’t be restricted as a default option. There is always a possibility to set up separate confidentiality agreements if needed.

Can BVH companies access AZ equipment and expertise? Yes. As long as AZ has the capacity and departmental approval has been obtained. Requests from BVH companies to use AZ expertise and equipment should be managed through the BVH team.

Is AZ reducing its footprint due to the BVH? No. Besides stimulating open and collaborative innovation, the BVH makes use of office and lab spaces that aren’t being used.

Does AstraZeneca have any rights in the BVH companies? Joining the BVH does not give AstraZeneca any rights to your company information nor to potential inventions/IP – not even a “first right of refusal”. As such, you have full freedom to operate as an independent company. No strings attached.

What AZ facilities can the BVH company employees access and use? All technical services and general facilities, e.g. restaurant, meeting rooms. BVH companies can operate under AstraZeneca’s environmental permit. BVH company employees can also access AstraZeneca’s sports centre if they have bought a membership card.

What kind of companies are you looking for to join the BVH? The BioVentureHub is an ideal environment for emerging medtech, biotech and digital health companies working on innovative life science. Please contact us if you have any thoughts or ideas about companies that could benefit from and add value to the BVH and AstraZeneca.

Where can I find more information about the BVH and BVH companies? Talk to the AZ BVH staff and BVH company employees, and check out: www.azbioventurehub.com or send an email to bioventurehub@astrazeneca.com

An Unexpected Incubation ModelPhilip M. Musey

For centuries, Gothenburg has been a nexus for the exchange of goods in and out of Sweden, linking the country with the rest of the world. As Scandina-via’s largest port, it has long been a harbor for new goods from around the globe. It’s no surprise, then, that Gothenburg is home to one of the most nov-el incubators in the world today: the AstraZeneca BioVenture Hub (BVH), which is, in its own right, a harbor for new ideas.

Magnus Björsne, CEO of BVH, calls it “a huge ex-periment in innovation management.” Sitting at the heart of AstraZeneca’s Gothenburg campus, the BVH is home to twenty-seven mid-stage companies in the life sciences and medtech space that all share one common goal: to advance the Scandinavian life sciences ecosystem. What do each of these com-panies get? Carte blanche access to the Gothen-burg campus. Wherever it makes sense, AstraZenca shares personnel, IP or cutting edge research that could potentially support the company in its growth. In return, AstraZeneca receives a modest rent pay-ment and a first look at investing in these companies when they’re ready to expand. AstraZeneca is able to share much of their IP with these companies with-out putting itself at risk. “It’s a system,” Björsne says, “that’s 100% based on trust.”

One such company is MentorMate, a global soft-ware development firm. MentorMate CEO Björn Stansvik attests that the BHV “rejects scarcity think-ing,” instead favoring a more inclusive and collabo-rative approach to Sweden’s vision for leading the world in digital health by 2025. Stansvik emphasizes that Sweden is a small nation that relies heavily on trade and commerce, and will only reach its goals if companies (large and small) work closely together. AstraZeneca is leading this charge in Sweden.

Why would one of the largest pharmaceutical com-panies in the world grant access to its wealth of hard-earned knowledge without a concrete prom-ise of something in return? The short answer: be-cause diversity drives innovation. This is the core idea behind Frans Johansson’s best-selling book on innovation, The Medici Effect — combining ele-ments from different fields, disciplines and domains will lead to better and oftentimes unexpected ideas.

It’s why, for example, AstraZeneca’s BVH has opened its doors to i-Tech, a company that sup-plies a patented anti-corrosive agent to marine paint manufacturers. The synergies between pharma and marine paint aren’t obvious, but “the point is to build an ecosystem to experiment,” says Björsne.

These collaborations don’t happen on their own, though. They are facilitated by Business Region Go-thenburg (BRG)—a government-backed non-profit supporting the BVH and other business develop-ment efforts in Gothenburg’s thirteen municipalities. According to Iris Öhrn, Investment Advisor with BRG, one of Sweden’s strategic advantages as a small country is its R&D capacity. Innovative ideas are the lifeblood of R&D, which is why BRG is heavi-ly promoting innovation through more partnerships, more connectivity and more cooperation between industry and trade groups.

Deep, meaningful collaboration is the future of innovation. What Business Region Gothenburg and AstraZeneca BioVenture Hub are doing in Gothen-burg is a macro-inclusive model for innovation that can serve as an example to the rest of the world.

Philip M. Musey is a Content Marketing Associate at The Medici Group, where he is responsible for telling stories about how harnessing differences and working at the Intersection enables anyone to create groundbreaking ideas.

The Medici Group enables companies to activate diversity to innovate, move faster, and transform their culture. Founded by Frans Johansson, author of The Medici Effect and one of the foremost thought leaders on diversity driving innovation, the firm works with CXOs to anchor diversity & inclusion at the center of innovation and strategy. Medici has worked with 30 percent of the Fortune 100, including Exelon, Nike, Novartis, Synchrony Financial, and The Walt Disney Company.

Article published on LinkedIn on December 6, 2018.

FINANCIAL OVERVIEW

SPONSORS

COSTS

We have divided project costs into three types for 2018:

Operating costs: amounted to SEK 3.2 million –mainly consisting of personnel costs

Infrastructure costs: amounted to SEK 0.2 million – establishing processes, IT infrastructure and other necessary infrastructure adjustments to support the innovation-focused environment.

Support to companies: amounted to SEK 1.3 million – costs for activities that have directly supported one or more BVH company.

In total, costs for 2018 amounted to SEK 4.7 million.

FUNDING(distribution of project costs)

VINNOVA (Sweden’s innovation agency) finances project costs corresponding to 50% of external financing.

Carl Bennet AB finances project costs corresponding to 16.7% of external financing.

Region Västra Götaland (VGR) finances project costs corresponding to 16.7% of external financing.

City of Gothenburg (Göteborgs stad) finances project costs corresponding to 16.7% of external financing.

We would like to sincerely thank all our sponsors, including AstraZeneca, which has provided tremendous in-kind support not accounted for in the numbers above.

In addition to AstraZeneca’s in-kind contribution, the BioVentureHub project is financed by four external sponsors with contributions and costs allocated as follows:

SCIENTIFIC PARTNERS

2120

Magnus BjörsneCEO

Pernilla IsbergCOO

Jamie SmithCommunications

Ramon NoguerasReal Estate

Erica WoodrowFinance/Coordinator

Annica JohanssonFacilities Management

THE BIOVENTURE HUB TEAM

2322

AZBIOVENTUREHUB.COM

Since launching

in October 2015,

17656 unique users

have now visited the

BioVentureHub website

during 24506 sessions

in 102 countries

TOP 10 COUNTRIES VISITING AZBIOVENTUREHUB.COM

1. Sweden (1)

2. United States (3)

3. United Kingdom (4)

4. Switzerland (2)

5. France (10)

6. Canada (-)

7. India (6)

8. Germany (7)

9. Brazil (8)

10. Denmark (5)

Numbers in brackets are 2017 ranking.

Special thanks go to the following people for going over and above the call of duty:

Martin Adler; Matti Ahlqvist; Marie Anderson; Katarina Ageborg; Mats Berglund; Elisabeth Björk; Kay Brickmann; Catharina Dahl; Petra Eurenius; Staffan Folestad; Robert Goude; Lubomir Gradinarski; Jan-Olof Jacke; Anita Klute; Niklas Magnell; Ulrika Lilja Stevall; Jacob Lund; Lars Sandberg; Stanko Skritic; Lars Västanhav.

SPECIAL THANKS

21% 14%UNIQUE USERS 2018 TOTAL SESSIONS 2018

@BioVentureHubazbioventurehub.com

To learn more about the BioVentureHub and companies, visit www.azbioventurehub.com or send an email to bioventurehub@astrazeneca.com

VERSION 1.0 © AstraZeneca BioVentureHub AB 2019 Produced by Jamie Smith Communications AB